Pages that link to "Q62731361"
Jump to navigation
Jump to search
The following pages link to The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum (Q62731361):
Displaying 50 items.
- The continuing challenges of leprosy (Q24545809) (← links)
- Thalidomide analogues as anticancer drugs (Q24670383) (← links)
- Treatment of cachexia: an overview of recent developments (Q26851540) (← links)
- The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro (Q28343837) (← links)
- The treatment of advanced renal cell cancer with high-dose oral thalidomide (Q28361231) (← links)
- Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity (Q28379160) (← links)
- The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy (Q30238551) (← links)
- Cancer cachexia: a therapeutic approach (Q31791590) (← links)
- Thalidomide (Q31825147) (← links)
- Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing (Q32111479) (← links)
- Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report (Q33454062) (← links)
- Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages (Q33594060) (← links)
- Tumour necrosis factor alpha and mucocutaneous leishmaniasis (Q33611149) (← links)
- Thalidomide as an emerging immunotherapeutic agent (Q33774204) (← links)
- Immunomodulation by thalidomide and thalidomide analogues (Q33782386) (← links)
- Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine (Q33853512) (← links)
- Thalidomide: current and potential clinical applications (Q33899122) (← links)
- Cachexia: a therapeutic approach beyond cytokine antagonism (Q33960631) (← links)
- Potential novel uses of thalidomide: focus on palliative care (Q34030108) (← links)
- Advances in inflammatory bowel disease (Q34057531) (← links)
- Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection (Q34102780) (← links)
- Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma (Q34193973) (← links)
- Immune deficiency presenting as mycobacterial infection (Q34195497) (← links)
- Thalidomide in gastrointestinal disorders (Q34277818) (← links)
- Optimal management of cancer anorexia-cachexia syndrome. (Q34417908) (← links)
- Thalidomide: an antineoplastic agent (Q34457441) (← links)
- Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro (Q34571693) (← links)
- Thalidomide in myelodysplastic syndromes (Q34571696) (← links)
- Thalidomide in cancer treatment: a potential role in the elderly? (Q34597832) (← links)
- Pharmacological aspects of human and canine narcolepsy (Q34740875) (← links)
- Treatment of pediatric refractory Crohn's disease with thalidomide (Q34744824) (← links)
- Thalidomide in dermatology (Q34992495) (← links)
- Molecular mechanisms of novel therapeutic approaches for multiple myeloma (Q35013215) (← links)
- Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview (Q35070041) (← links)
- Thalidomide: A review of approved and investigational uses (Q35128432) (← links)
- Novel therapeutic approaches for multiple myeloma (Q35170935) (← links)
- Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease (Q35198923) (← links)
- Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals. (Q35410293) (← links)
- Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production (Q37426004) (← links)
- A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum (Q37695062) (← links)
- Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B. (Q38300574) (← links)
- A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans (Q39474820) (← links)
- Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro (Q39531106) (← links)
- Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-α and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line (Q39687272) (← links)
- Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety (Q40077663) (← links)
- Malignant causes of fever of unknown origin. (Q40153526) (← links)
- Transport of thalidomide by the human intestinal caco-2 monolayers (Q40398700) (← links)
- Recombinant cytokines for controlling mycobacterial infections (Q40508105) (← links)
- IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells (Q40535859) (← links)
- Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. (Q40921115) (← links)